EA200601227A1 - Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов - Google Patents

Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов

Info

Publication number
EA200601227A1
EA200601227A1 EA200601227A EA200601227A EA200601227A1 EA 200601227 A1 EA200601227 A1 EA 200601227A1 EA 200601227 A EA200601227 A EA 200601227A EA 200601227 A EA200601227 A EA 200601227A EA 200601227 A1 EA200601227 A1 EA 200601227A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rotigotine
treatment
prevention
death
dopaminergic neurons
Prior art date
Application number
EA200601227A
Other languages
English (en)
Other versions
EA014418B1 (ru
Inventor
Дитер Шеллер
Франк Дрессен
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34706587&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200601227(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200601227A1 publication Critical patent/EA200601227A1/ru
Publication of EA014418B1 publication Critical patent/EA014418B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Данное изобретение относится к применению ротиготина или его солей и пролекарств для изготовления лекарства для лечения или предотвращения деструкции дофаминергических клеток при заболеваниях, которые связаны с повышенной деструкцией дофаминергических клеток. Изобретение также относится к применению ротиготина в качестве лекарства для превентивного лечения болезни Паркинсона.
EA200601227A 2003-12-24 2004-12-23 Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов EA014418B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10361259A DE10361259A1 (de) 2003-12-24 2003-12-24 Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
PCT/EP2004/014655 WO2005063237A1 (de) 2003-12-24 2004-12-23 Verwendung von rotigotin zur behandlung oder zur prävention des dopaminergen neuronenverlustes

Publications (2)

Publication Number Publication Date
EA200601227A1 true EA200601227A1 (ru) 2006-12-29
EA014418B1 EA014418B1 (ru) 2010-12-30

Family

ID=34706587

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601227A EA014418B1 (ru) 2003-12-24 2004-12-23 Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов

Country Status (20)

Country Link
EP (1) EP1696904B1 (ru)
JP (1) JP5032125B2 (ru)
KR (1) KR101296561B1 (ru)
CN (1) CN1897935B (ru)
AT (1) ATE533484T1 (ru)
AU (1) AU2004308648B2 (ru)
BR (1) BRPI0418195A (ru)
CA (1) CA2547645C (ru)
DE (1) DE10361259A1 (ru)
DK (1) DK1696904T3 (ru)
EA (1) EA014418B1 (ru)
ES (1) ES2376881T3 (ru)
HK (1) HK1094538A1 (ru)
IL (1) IL175891A0 (ru)
IS (1) IS8493A (ru)
NO (1) NO20063276L (ru)
NZ (1) NZ547841A (ru)
PL (1) PL1696904T3 (ru)
UA (1) UA85858C2 (ru)
WO (1) WO2005063237A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C1 (ru) * 2016-07-21 2020-03-24 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
CN103149368B (zh) * 2005-10-21 2015-06-10 株式会社芳珂 特应性皮炎标记物及其利用技术
CN101147739B (zh) 2007-07-06 2010-12-08 北京康倍得医药技术开发有限公司 含罗替戈汀的组合物及其制药用途以及含该组合物的透皮贴剂
SG10201610626PA (en) 2007-11-28 2017-01-27 Ucb Pharma Gmbh Polymorphic form of rotigotine
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
EP3257504A1 (en) 2009-12-22 2017-12-20 UCB Biopharma SPRL Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
WO2011095539A2 (en) 2010-02-05 2011-08-11 Ucb Pharma Gmbh Novel process for the preparation of nitrogen substituted aminotetralins derivatives
MX2012013818A (es) 2010-06-25 2013-01-24 Ucb Pharma Gmbh Procesos para la resolucion de derivados de (s)-5-alcoxi-2-amino-t etralina sustituida con nitrogeno.
CN102379873B (zh) * 2010-09-06 2013-10-30 四川大学华西医院 一种急性全身性猴帕金森病模型及其药物筛选方法
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013075823A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
BR112015032929B1 (pt) 2013-07-03 2022-08-23 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico com componente eletrônico e métodos de produção de um sistema terapêutico transdérmico
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN106456566B (zh) * 2014-05-20 2020-06-16 Lts勒曼治疗***股份公司 含罗替戈汀的经皮递送***
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗***股份公司 包含界面调节剂的经皮递送***
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
PT3854388T (pt) 2020-01-24 2023-12-11 Luye Pharma Switzerland Ag Sistema terapêutico transdérmico com o princípio ativo rotigotina e pelo menos um adesivo de silicone não resistente a aminas
CN112014193B (zh) * 2020-07-24 2021-06-15 武汉大学中南医院 一种新的fj染色方法和装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
CO5111024A1 (es) * 1998-12-29 2001-12-26 Kimberly Clark Co Composiciones de recubrimientos de polimero disparado por ion sobre peliculas de polimero sensibles al agua
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
WO2002031499A1 (en) * 2000-10-09 2002-04-18 Unisearch Limited Detection of neurodegenerative disorders
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
DE60100994T2 (de) * 2001-05-08 2004-07-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
FR2828212B1 (fr) * 2001-08-03 2003-10-31 Aventis Pharma Sa Methodes de diagnostic et de pronostic de la maladie de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C1 (ru) * 2016-07-21 2020-03-24 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Also Published As

Publication number Publication date
DK1696904T3 (da) 2012-02-13
HK1094538A1 (en) 2007-04-04
KR20060109952A (ko) 2006-10-23
CA2547645C (en) 2013-07-16
AU2004308648A1 (en) 2005-07-14
CN1897935A (zh) 2007-01-17
IS8493A (is) 2006-05-31
JP5032125B2 (ja) 2012-09-26
CA2547645A1 (en) 2005-07-14
AU2004308648B2 (en) 2010-12-16
ES2376881T3 (es) 2012-03-20
BRPI0418195A (pt) 2007-06-19
EP1696904A1 (de) 2006-09-06
UA85858C2 (ru) 2009-03-10
EP1696904B1 (de) 2011-11-16
JP2007516996A (ja) 2007-06-28
NZ547841A (en) 2011-02-25
PL1696904T3 (pl) 2012-04-30
IL175891A0 (en) 2006-10-05
KR101296561B1 (ko) 2013-08-13
CN1897935B (zh) 2010-05-26
NO20063276L (no) 2006-08-30
WO2005063237A1 (de) 2005-07-14
EA014418B1 (ru) 2010-12-30
ATE533484T1 (de) 2011-12-15
DE10361259A1 (de) 2005-07-28

Similar Documents

Publication Publication Date Title
EA200601227A1 (ru) Применение ротиготина для лечения или предотвращения гибели дофаминергических нейронов
CR7785A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
MX2010008706A (es) Derivados de fenil-prenilo, de origen marino y sintetico. para el tratamiento de enfermedades o trastornos cognitivos, neurodegenerativos o neuronales.
WO2012083128A3 (en) Prevention and treatment of diseases characterized by mesencephalic dopaminergic neuron cell death
IL197035A0 (en) Pharmaceutical formula for treating skin disease
UY27348A1 (es) Imidazotriazinas
HN2002000271A (es) 2,5 diamidoindoles sustituidos y su utilizacion.
TR201900152T4 (tr) Sinükleinopatik ve amiloidojenik hastalıkların önlenmesi ve tedavisi.
DOP2003000728A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenetivos
EA200900313A1 (ru) Производные бензо[1,2,3]тиадиазина

Legal Events

Date Code Title Description
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU